Mylan to challenge court decision over generic asthma, COPD drug
Drug maker had sought approval for generic version of Sunovion's Xopenex
February 14, 2012
Generic drug maker Mylan plans to challenge a court decision that requires it to pay almost $20 million to a drug company whose product it tried to market as a generic.
Want to Read More?
This content is available only to registered users. Log in to read the rest of this article or create a free account.